

**Amendments to the Claims:**

This listing of claims replaces all prior versions and listings of claims in the application:

**Listing of Claims:**

1. **(Currently Amended)** A combination product comprising a positive oil in water emulsion wherein said emulsion comprises ~~a compound at least one cationic lipid presenting free NH<sub>2</sub> groups selected from the group consisting of a C<sub>10</sub>-C<sub>24</sub> alkylamine, a C<sub>10</sub>-C<sub>24</sub> alkanolamine and a cholesterol ester, at its natural state~~, at the oil-water interface, and an antibody, wherein said compound is linked to said antibody by a heterobifunctional linker, ~~linking said NH<sub>2</sub> groups to SH groups on the antibody hinge region.~~
2. **(Original)** The combination product of claim 1 wherein said product has a positive zeta charge.
3. **(Cancelled)**
4. **(Currently Amended)** The combination product of claim 3, wherein said cationic lipid ~~compound presenting NH<sub>2</sub> free groups~~ is stearylamine or oleylamine.
5. **(Currently Amended)** The combination product of claim 1, wherein said emulsion comprises colloid particles having an oily core surrounded by an interfacial film, wherein said interfacial film comprises said cationic lipid ~~compound presenting free NH<sub>2</sub> at its natural state~~, nonionic surfactant and an anionic surfactant or anionic lipid, wherein said colloidal particles have a positive zeta potential.
6. **(Previously Presented)** The combination product of claim 5, wherein said emulsion contains an active principle (drug).
7. **(Previously Presented)** The combination product of claim 1, wherein said antibody is a polyclonal antibody.

8. **(Previously Presented)** The combination product of claim 1, wherein said antibody is a monoclonal antibody selected from the group comprising native forms, synthetic forms, chimeric forms and humanized forms.

9. **(Previously Presented)** The combination product of claim 1, wherein said antibody targets an antigen present at the surface of a pathological cell.

10. **(Previously Presented)** The combination product of claim 1, wherein said antibody targets a protein selected from the group comprising HER-2, H-ferritin, PSMA, mucins, MUC 1, CD 44 and retinal S-Ag.

11. **(Currently Amended)** The combination product of claim 1, wherein said antibody is AMB8LK ~~ANB8LK~~ antibody.

12. **(Previously Presented)** The combination product of claim 1, wherein said linker is chosen from N-1 stearyl-maleimide (SM), oleyl-maleimide, succinimidyl trans-4-(maleimidylmethyl)cyclohexane-1-carboxylate (SMCC) and succinimidyl 3-(2-pyridyldithio)propionate (SPDP).

13. **(Currently Amended)** A method for producing a combination product according to claim 1, comprising the steps of:

- a) optionally reducing an antibody in order to obtain free SH group on its hinge region,
- b) mixing a positive emulsion wherein said emulsion comprises at least one cationic lipid presenting free NH<sub>2</sub> groups selected from the group consisting of a C<sub>10</sub>-C<sub>24</sub> alkylamine, a C<sub>10</sub>-C<sub>24</sub> alkanolamine and a cholesterol ester ~~a compound which~~, at its natural state, ~~contains free NH<sub>2</sub> groups~~, wherein said cationic lipid compound is linked to a heterobifunctional linker by said NH<sub>2</sub> groups, with the antibody presenting free SH groups in order to obtain said combination product.

14. **(Currently Amended)** The method of claim 13, wherein said positive emulsion in step b) is obtained by emulsion:

- i. linking a linker to a free NH<sub>2</sub> group naturally present on a cationic lipid compound that is used to obtain a positive emulsion, in order to obtain a modified compound,
- ii. mixing said modified cationic lipid compound, which at its natural state contains free NH<sub>2</sub> groups, with ~~the other products necessary to obtain an emulsion, which are~~ water, oil and an emulsifying agent, in order to obtain a positive emulsion.

15. **(Currently Amended)** The method of claim 13, wherein said positive emulsion in step b) is obtained by:

- i. mixing a cationic lipid compound, which at its natural state contains free NH<sub>2</sub> groups, with ~~the other products necessary to obtain an emulsion,~~ water, oil and an emulsifying agent in order to obtain a positive emulsion,
- ii. linking a linker to a free NH<sub>2</sub> group naturally present on said cationic lipid compound, in order to obtain a modified cationic lipid compound within said positive emulsion.